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Extracellular matrix and soluble plasma proteins generate
peptides that regulate biological activities such as cell
growth, differentiation and migration. Bradykinin, a pep-
tide released from kininogen by kallikreins, stimulates
vasodilatation and endothelial cell proliferation. Various
classes of substances can potentiate these biological
actions of bradykinin. Among them, the best studied are
bradykinin potentiating peptides (BPPs) derived from
snake venom, which can also strongly inhibit angiotensin
I-converting enzyme (ACE) activity. We identified and
synthesized sequences resembling BPPs in the vicinity
of potential proteolytic cleavage sites in the collagen XVIII
molecule, close to endostatin. These peptides were
screened as inhibitors of human recombinant wild-type
ACE containing two intact functional domains; two full-
length ACE mutants containing only a functional C- or N-
domain catalytic site; and human testicular ACE, a
natural form of the enzyme that only contains the C-
domain. The BPP-like peptides inhibited ACE in the
micromolar range and interacted preferentially with the
C-domain. The proteolytic activity involved in the release
of BPP-like peptides was studied in human serum and
human umbilical-vein endothelial cells. The presence of
enzymes able to release these peptides in blood led us
to speculate on a physiological mechanism for the con-
trol of ACE activities.
Keywords: ACE inhibitors; angiogenesis; bradykinin
potentiating peptides; endostatin.
Introduction
Endostatin, an inhibitor of angiogenesis and tumor
growth, was first shown to be produced by a cell line
derived from a non-metastatic murine hemangioendothe-
lioma (EOMA) (O’Reilly et al., 1997). Endostatin is gen-
erated by proteolysis of collagen XVIII, which is the core
protein of a heparan sulfate proteoglycan found in vas-
cular and epithelial basement membranes. Collagen XVIII
is part of a distinct subgroup within the collagen super-
family characterized by multiple interruptions in the cen-
tral triple-helical domain and a unique non-triple-helical
domain at the C-terminus, non-collagenous-1 (NC1)
domain. This NC1 domain of collagen XVIII consists of a
5-kDa N-terminal association domain that is implicated
in self-assembly of the homotrimeric collagen XVIII; a
central protease-sensitive hinge domain; and a compact
22-kDa C-terminal endostatin domain (Sasaki et al.,
1998). The central protease-sensitive hinge domain of the
NC1 domain of collagen XVIII is cleaved into smaller frag-
ments ranging from 22 to 32 kDa (Sasaki et al., 1998;
Marneros and Olsen, 2001; Iozzo, 2005) by different pro-
teases such as cathepsin L (Felbor et al., 2000), MMPs
(Ferreras et al., 2000; Lin et al., 2001; Heljasvaara et al.,
2005) or pancreatic elastase (Wen et al., 1999), gener-
ating distinct endostatin-containing fragments with vary-
ing efficiency. Lysosomal proteases seem to be involved
not only in the generation of endostatin, but also in its
degradation (Ferreras et al., 2000).
The NC1 domain sequences of human and mouse col-
lagen XVIII are not conserved and the size and sequenc-
es are quite different in both organisms. Figure 1 shows
the sequence of the human collagen XVIII hinge domain
and the cleavage sites for different matrix metallopro-
teases (MPPs) and cathepsin L as reported previously
(Felbor et al., 2000; Heljasvaara et al., 2005). The N-ter-
minal pro-segment of human endostatin contains the
sequence LRPARTPSPP (underlined in Figure 1) that is
similar to the sequences of the bradykinin potentiating
peptides (BPPs) isolated from Botrops jararaca snake
venom (Ferreira, 1965; Ianzer et al., 2004). These pep-
tides are efficient natural angiotensin I-converting
enzyme (ACE) inhibitors and their structure-activity stud-
ies were the basis for the development of anti-hyperten-
sive drugs such as captopril and various analogs
(Cushman and Ondetti, 1980). However, in the last three
decades, different explanations for the BPP potentiating
mechanism demonstrated that the enhancement of BK
activity cannot be entirely due to ACE inhibition (revised
by Erdös and Marcic, 2001). Recently, Mueller et al.
(2005), studying synthetic analogs of the bradykinin
potentiating peptide BPP9a, provided evidence that ACE
inhibition and the bradykinin potentiating activity occur
by different mechanisms.
ACE is anchored to the plasma membrane of endothe-
lial cells and is involved in the modulation of angioge-
nesis (Volpert et al., 1996; Fabre et al., 1999; Silvestre et
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Figure 1 Amino acid sequence of the hinge domain and the N-terminal sequence of endostatin from the NC1 domain of human
collagen XVIII.
The cleavage sites for MMPs (Heljasvaara et al., 2005) and cathepsin L (Felbor et al., 2000) are indicated. The beginning of the
endostatin sequence was arbitrarily assigned as the same site described for mouse endostatin (Sasaki et al., 1998). The underlined
sequence LRPARPTSTSPP corresponds to the BPP-like sequence. Modifications in mouse collagen XVIII in this sequence are indi-
cated below the human sequence.
Table 1 Inhibition constants (Ki) for angiotensin I-converting enzyme activity with synthetic
peptides derived from human collagen XVIII hinge domain with sequences similar to brady-
kinin potentiating peptides (BPPs) from snake venom.
No. Sequence Ki (mM)
Testis ACE Wildtype C-domain N-domain
I SPP 5.0 6.9 19 13
II PARPTSPP 1.5 5.3 2.1 49
III RPARPTSPP 1.0 6.8 0.9 23
IV LRPARPTSPP 0.8 2.6 3.2 17
V YVHLRPARPTSPP 0.8 5.8 2.0 10
VI SSYVHLRPARPTSPP 2.4 7.7 3.1 200
VII LRPARPTSPPA 0.3 17 4.6 12
VIII (pE)KWAP (BPP5a) 0.8 0.4 0.7 0.6
IX (pE)WPRPQIPP (BPP9a) 0.01 0.03 0.003 0.1
Kinetic conditions: the enzymes were pre-incubated with increasing concentrations of pep-
tides I–IX for 3 min at 378C in 0.1 M Tris-HCl buffer, pH 7.0, containing 0.05 M NaCl and
10 mM ZnCl2. The reaction was initiated by the addition of Abz-YRK(Dnp)P-OH (10 mM) at
378C in a final volume of 2 ml. Measurements were made in duplicate and differences were
less than 5%. pE, pyroglutamic acid.
al., 2001; Yoshiji et al., 2001). In addition, ACE activity
was reported to increase angiogenesis and cellular pro-
liferation (Lindberg et al., 2004) through angiotensin-II-
induced VEGF expression (Fujita et al., 2002) and AT1
receptors (Lorell, 1999), and both effects were decreased
by treatment with ACE inhibitors (Small et al., 1997; Hii
et al., 1998). The opposite effect of ACE inhibition has
been reported, highlighted in the context of angiogenesis
(Small et al., 1997; Hii et al., 1998; Silvestre et al., 2001),
through increasing levels of angiotensin II, bradykinin and
VEGF signaling (Williams et al., 1995; Pupilli et al., 1999),
all of which are involved in endothelial proliferation.
The hydrolysis pattern of the protease-sensitive hinge
domain of collagen XVIII (Figure 1) suggests the cleavage
and release of peptides containing BPP-like sequences,
such as LRPARPTSPPA, as well as longer or shorter
regions of this peptide. Owing to the role of ACE in the
control of angiogenesis via angiotensin II and bradykinin,
we investigated the inhibition of four forms of ACE by
synthetic peptides with sequences derived from human
collagen XVIII that contain the BPP-like peptides. We
report on the inhibition of three human recombinant ACE
proteins, namely wild-type protein containing two intact
functional domains and two full-length ACE mutants con-
taining only one functional catalytic site (referred to as
the C- or N-domain) by these peptides. They were also
tested as inhibitors of a purified human testicular ACE, a
natural form of the enzyme that only contains the C-
domain. We also examined the hydrolysis of synthetic
peptides of human collagen XVIII by recombinant human
cathepsins B, K and L. These peptides were also
assayed with human serum and with an established line-
age of human umbilical-vein endothelial cells.
Results
Peptides derived from the C-terminal NC1 domain
of human collagen XVIII as ACE inhibitors
The FRET substrate Abz-YRK(Dnp)P-OH was used to
evaluate ACE activity (Araujo et al., 2000) and to compare
the inhibition profiles of the peptides derived from the
C-terminal NC1 domain of human collagen XVIII. The
N- and C-termini of these peptides (Table 1) were unpro-
tected and were resistant to hydrolysis by all forms of
ACE studied. Moreover, they displayed competitive inhi-
bition, with Ki values in the micromolar range.
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Figure 2 Cleavage sites in the peptide Abz-RPTSPPAH-
SHRDFQPVLHLVALNSPL-NH2 of human cathepsins B, K and L.
The cleavage sites were determined as described in the mate-
rials and methods section.
Figure 3 HPLC profile of the peptide Abz-RPTSPPAH-
SHRDFQPVLHLVALNSPL-NH2 before and after incubation for 8,
24 and 48 h with human serum (A) and HUVEC supernatant (B).
Incubation conditions are described in the materials and meth-
ods section. Fractions were monitored by fluorescence at
lexs320 nm and lems420 nm.
Testicular ACE, which contains only the C-domain, was
more efficiently inhibited by peptides I–VII (Table 1) than
the other forms of ACE assayed. The specificity of these
peptides for the ACE C-domain was also observed with
the mutant enzyme with only the C-domain active. This
C-domain selectivity was also observed for BPP9a (pep-
tide IX, Table 1), in accordance with earlier reports
regarding the domain selectivity of BPPs (Cotton et al.,
2002). Furthermore, this peptide inhibited all forms of
ACE in the nanomolar range, which indicates that the
amino acids that precede the pair of Pro residues play a
significant role in the interaction of BPPs with the non-
prime sites of ACE.
Hydrolysis of the sequence connecting the hinge
domain and endostatin in human collagen XVIII by
human cathepsins B, L and K, human serum and
endothelial cell proteases
Cathepsin B, L and K hydrolysis of the peptide Abz-
RPTSPPAHSHRDFQPVLHLVALNSPL-NH2 containing the
hinge sequence between the BPP-like peptide (RPTSPP)
and the N-terminal region of endostatin, resulted in
cleavage of three peptide bonds as determined by HPLC
and mass spectrometry (Figure 2). The three cathepsins
cleaved at the H-L bond, cathepsins B and L also
cleaved at the L-H bond, and only cathepsin L cleaved
at the A-L bond. This peptide was more efficiently hydro-
lyzed by cathepsin L, followed by cathepsin B; however,
none of the cathepsins was able to release the RPTSPP
fragment that corresponds to the BPP-like peptide.
We also investigated the presence of proteolytic activ-
ity in human serum (Figure 3A) and HUVEC cell culture
(Figure 3B) that could generate a peptidic ACE inhibitor
from Abz-RPTSPPAHSHRDFQPVLHLVALNSPL-NH2. In-
cubation with serum or with HUVECs showed that the
fragment Abz-RPTSPPA, corresponding to hydrolysis at
the A-H bond, was detected after 8 h and remained intact
even after 48 h, as demonstrated by HPLC analysis and
mass spectrometry. Pre-incubation of human serum with
pepstatin A, E-64 and ortho-phenanthroline (aspartyl,
cysteine and metallopeptidase inhibitors, respectively)
did not inhibit peptide cleavage. Only PMSF, a serine
peptidase inhibitor, was effective in blocking cleavage.
Discussion
Endothelial ACE exerts its physiological effects through
two distinct routes: the renin-angiotensin system by angi-
otensin II production, a potent vasopressor peptide also
involved in cellular proliferation through the AT1 receptor;
and the kininogen-kinin system by bradykinin degra-
dation, a vasodilator peptide involved in angiogenesis
through the inflammation-inducible B1 and constitutively
expressed B2 receptors. B1 signaling plays an important
role in reparative angiogenesis in post-ischemic limbs
(Emanueli et al., 2002) and rabbit cornea (Parenti et al.,
2001), whereas its antagonism results in apoptosis.
Using a model of surgically induced hind-limb ischemia,
Silvestre et al. (2001) showed that the proangiogenic
effect of ACE inhibitors is also mediated by the B2 recep-
tors. The B2 signaling pathway is also responsible for
nitric oxide and prostaglandin release (Regoli and
Barabe, 1980), which contribute to endothelial cell prolif-
eration, a system that enhances VEGF signaling.
BPPs are natural ACE inhibitors first reported in
Bothrops jararaca venom (Ferreira, 1965). Later, other
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BPPs were isolated from the venom of other snakes
(Kato and Suzuki, 1971; Cintra et al., 1990; Ferreira et al.,
1992), spiders (Akchumov et al., 1992) and scorpions
(Ferreira et al., 1993). Peptides with bradykinin potentia-
ting activity can also be formed by hydrolysis of proteins
taken from serum (Yamafuji et al., 1996), hemoglobin
(Piot et al., 1992; Ivanov et al., 1997), and milk (Henriques
et al., 1987; Lebrun et al., 1995). The main effects of
natural ACE inhibition are not restricted to the reduction
of angiotensin II production, but also include a decrease
in bradykinin degradation, synergistically leading to sev-
eral outcomes in the progression of the cell cycle. Most
BPPs are enriched in internal proline residues, which
confer resistance to cleavage by aminopeptidades, car-
boxypeptidases and endopeptidases present in human
plasma (Ferreira et al., 1970; Freer and Stewart, 1971).
The presence in the hinge domain of a sequence
enriched in proline residues and its localization near to
endostatin in human collagen XVIII make it tempting to
speculate about the existence of combined physiological
roles of endostatin and BPPs from human collagen XVIII
in the control of angiogenesis. All peptides (I–VII in Table
1) derived from the hinge domain inhibited all forms of
ACE in this study, with Ki values two or three orders of
magnitude higher than BPP9a, the most efficient natural
inhibitor of ACE. However, for physiological control and
owing to the possible local release from collagen XVIII,
the BPP-like peptides could be effective in human tis-
sues. It is important to note that the peptides assayed in
the present study contain peculiar sequences of prolines
not found in mice collagen (Figure 1). Endostatin and
BPP-like peptides can be released from human collagen
XVIII by the proteolytic activity of lysosomal proteases,
particularly cathepsin L and MMPs, as illustrated in Fig-
ure 1. In addition, another candidate protease in human
serum and in HUVECs could be a serine protease that
was able to hydrolyze the peptide Abz-RPTSPPAH-
SHRDFQPVLHLVALNSPL-NH2 at the A-H bond, releas-
ing the ACE inhibitory peptide RPTSPPA.
In conclusion, the discrepancy between in vitro and in
vivo endostatin strength of action, which is attenuated in
vivo, could be related to the absence of other factors
present, such as peptides with ACE inhibitory properties.
Although the simultaneous activities of endostatin and
ACE inhibitors on angiogenesis control are speculative,
until recently there has been little molecular information
about endogenous ACE fine-tuning of angiogenesis reg-
ulation. The effects of natural BPPs on angiogenesis and
tumorigenesis require further investigation and we are
currently pursuing these areas of interest.
Materials and methods
Materials
The protease inhibitors pepstatin A, trans-epoxysuccinyl-L-leu-
cylamido-(4-guanidino) butane (E-64), ortho-phenanthroline,
phenylmethylsulfonyl fluoride (PMSF), BPP5a and BPP9a were
purchased from Sigma (St. Louis, MO, USA). DMEM:F12 was
from Gibco (Gaithersburg, USA) and fetal bovine serum was
from Cultlab (Campinas, Brazil).
Synthetic peptides
All peptides assayed as inhibitors were synthesized using a sol-
id-phase technique. The fluorescence resonance energy transfer
(FRET) peptide Abz-YRK(Dnp)P-OH, (Abzsortho-aminobenzoic
acid; Dnps2,4-dinitrophenyl) was synthesized using Fmoc-
Lys(Dnp)-OH and H-Pro-2-chlorotrityl resin (Araujo et al., 2000).
The FRET peptide Abz-RPTSPPAHSHRQ-EDDnp (EDDnpsethy-
lene diamine-2-4-dinitrophenyl) was also synthesized using a
solid-phase method (Hirata et al., 1994) with the Fmoc proce-
dure. An automated bench-top simultaneous multiple solid-
phase peptide synthesizer (PSSM 8 system; Shimadzu, Kyoto,
Japan) was used for all syntheses. The peptides were purified
by semi-preparative HPLC using an Econosil C-18 column. The
molecular mass and purity of the synthesized peptides were
checked by amino acid analysis and matrix-assisted laser-
desorption ionization time-of-flight (MALDI-TOF) mass spec-
trometry, using a TOFSpec E instrument (Micromass,
Manchester, UK). Stock solutions of Dnp or EDDnp peptides
were prepared in DMSO, and the concentrations were measured
spectrophotometrically using a molar absorption coefficient of
17 300 M-1 cm-1 at 365 nm.
Enzymes
Human testicular ACE was prepared as previously reported
(Woodman et al., 2000). The three human recombinant forms of
ACE, namely the wild-type form and the two full-length ACE
mutants containing only one intact catalytic site, were kindly
supplied by Dr. Dulce Elena Casarini (Universidade Federal de
São Paulo, Brazil). The enzymes were obtained through stable
expression in CHO cells as previously described (Wei et al.,
1991). The molar concentrations of the ACE enzymes were
determined by active-site titration with the tight-binding inhibitor
lisinopril as previously described (Ehlers and Riordan, 1991).
Recombinant human cathepsins L and B were expressed as
previously described (Carmona et al., 1996; Nagler et al., 1997).
Cathepsin K was kindly supplied by Dr. Dieter Brömme from the
University of British Columbia (Vancouver, Canada). The molar
concentrations of the cathepsins were evaluated by active-site
titration with the cysteine peptidase inhibitor E64 as previously
reported (Barrett and Kirschke, 1982).
Inhibition assays
ACE inhibition experiments were performed with the three forms
of recombinant human wild-type ACE and with human testicular
ACE. ACE activity on Abz-YRK(Dnp)P-OH was continuously
measured at 378C in a Shimadzu RF-1501 PC spectrofluorimeter
adjusted to lexs320 nm and lems420 nm. The assays were per-
formed in 0.1 M Tris-HCl buffer, pH 7.0, containing 0.05 M NaCl
and 10 mM ZnCl2. Inhibition assays were carried out under the
same conditions after 3-min pre-incubation of the enzymes with
increasing concentrations of BPP-like peptides. Fluorescence
emission was continuously measured and apparent inhibition
constant (Kiapp) values were obtained using the equation
w xIV0 s1q ,
V K1 iapp
where V0 and Vi are the velocity for less than 2% substrate
hydrolysis in the absence and presence of different inhibitor con-
centrations wIx, respectively. The assays were performed in dupli-
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Processing of peptides derived from the NC1
fragment of collagen XVIII by human recombinant
cathepsins B, K and L
Hydrolysis by cathepsins B, L and K (4 nM) of 20 mM Abz-
TSPPAHSHRDFQPVLHLVALNSPL-NH2 was carried out in
100 mM sodium acetate, 1 mM EDTA, pH 6.0. The incubations
were performed at 378C and aliquots were analyzed after 8, 24
and 48 h. The scissile bonds were identified by isolating the
fluorescent peptides on HPLC and determining their sequences
using MALDI-TOF mass spectrometry.
Processing of peptides derived from the NC1 region
of collagen XVIII by human serum
Human whole blood was collected and a clot was allowed to
form and shrink. Unclotted blood was centrifuged at 2000 g for
30 min and the serum supernatant was used in experiments.
Serum proteolytic activity was determined using substrates Abz-
RPTSPPAHSHRQ-EDDnp (20 mM) and Abz-TSPPAHSHRDFQP
VLHLVALNSPL-NH2 (20 mM) in 0.1 M Tris-HCl containing 135 mM
NaCl, pH 7.4, at 378C. The inhibition profile was measured by
pre-incubating reaction aliquots with 10 mM pepstatin A, 10 mM
PMSF, 5 mM E-64 or 1 mM ortho-phenanthroline (aspartyl-, ser-
ine-, thiol- and metallo-protease inhibitors, respectively). Ali-
quots were taken at different times over a period of 48 h and
the scissile peptide bonds were identified by isolation of the flu-
orescent fragments on HPLC, with sequences determined by
mass spectrometry, as described above.
Processing of peptides derived from the NC1
domain of collagen XVIII by human endothelial cells
Human umbilical-vein endothelial cells (HUVECs) were cultured
in DMEM:F12 medium supplemented with 20% fetal bovine
serum, penicillin (100 U/ml) and streptomycin (0.1 mg/ml). The
cells were maintained at 378C in 5% CO2/95% air and were
seeded into six-well plates (Falcon Co.) and grown to conflu-
ence. The proteolytic activity of membrane-bound and secreted
proteases was assayed using 20 mM Abz-RPTSPPAHSHRQ-
EDDnp, washing the monolayer twice with buffered saline solu-
tion and incubating peptides in the same buffer at 378C in 5%
CO2/95% air. Aliquots were taken and the cleavage sites were
identified by HPLC/mass spectrometry analysis, as already
described.
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J. (2000). Generation and degradation of human endostatin
proteins by various proteinases. FEBS Lett. 486, 247–251.
Freer, R.J. and Stewart, J.M. (1971). Synthetic bradykinin-poten-
tiating peptides related to those isolated from snake venom.
Ciencia Cultura 23, 539–542.
Fujita, M., Hayashi, I., Yamashina, S., Itoman, M., and Majima,
M. (2002). Blockade of angiotensin AT1a receptor signaling
reduces tumor growth, angiogenesis and metastasis. Bio-
chem. Biophys. Res. Commun. 294, 1450–1456.
Heljasvaara, R., Nyberg, P., Luostarinen, J., Parikka, M., Heikkila,
P., Rehn, M., Sorsa, T., Salo, T., and Pihlajaniemi, T. (2005).
Generation of biologically active endostatin fragments from
human collagen XVIII by distinct matrix metalloproteases.
Exp. Cell Res. 307, 292–304.
Henriques, O.B., de Jesus, R.B., and Santos, R.A. (1987). Bra-
dykinin potentiating peptides isolated from a-casein tryptic
hydrolysate. Biochem. Pharmacol. 36, 182–184.
Hii, S.-I., Nicol, D.L., Gotley, D.C., Thompson, L.C. Green, M.K.,
and Jonsson, J.R. (1998). Captopril inhibits tumour growth in
a xenograft model of human renal cell carcinoma. Br. J. Can-
cer 77, 880–883.
Hirata, I.Y, Cezari, M.H.C., Nakaie, C.R., Boshcov, P., Ito, A.S.,
Juliano, M.A., and Juliano, L. (1994). Internally quenched
fluorogenic protease substrates: Solid-phase synthesis and
fluorescent spectroscopy of peptides containing ortho-ami-
616 S.L. Farias et al.
Article in press - uncorrected proof
nobenzoyl-dinitrophenyl groups as donor-acceptor pairs.
Lett. Pept. Sci. 1, 299–308.
Ianzer, D., Konno, K., Marques-Porto, R., Portaro, F.C., Stocklin,
R., Camargo, A.C.M., and Pimenta, D.C. (2004). Identification
of five new bradykinin potentiating peptides (BPPs) from
Bothrops jararaca crude venom by using electrospray ioni-
zation tandem mass spectrometry after a two-step liquid
chromatography. Peptides 25, 1085–1092.
Iozzo, R.V. (2005). Basement membrane proteoglycans: from
cellar to ceiling. Nat. Rev. Mol. Cell. Biol. 6, 646–656.
Ivanov, V.T., Karelin, A.A., Philippova, M.M., Nazimov, I.V., and
Pletnev, V.Z. (1997). Hemoglobin as a source of endogenous
bioactive peptides: the concept of tissue-specific peptide
pool. Biopolymers 43, 171–178.
Kato, H. and Suzuki, T. (1971). Bradykinin-potentiating peptides
from the venom of Agkistrodom halys blomhoffi. Isolation of
five bradykinin potentiators and the amino acid sequences
of two of them, potentiators B and C. Biochemistry 10,
972–980.
Lebrun, I., Lebrun, F.L.A.S., Henriques, O.B., Carmona, A.K.,
Juliano, L., and Camargo, A.C.M. (1995). Isolation and char-
acterization of a new bradykinin potentiating octapeptide
from g-casein. Can. J. Physiol. Pharmacol. 73, 85–91.
Lin, H.C., Chang, J.H., Jain, S., Gabison, E.E., Kure, T., Kato, T.,
Fukai, N., and Azar, D.T. (2001). Matrilysin cleavage of cor-
neal collagen type XVIII NC1 domain and generation of a 28-
kDa fragment. Invest. Ophthalmol. Vis. Sci. 42, 2517–2524.
Lindberg, H., Nielsen, D., Jensen, B.V., Eriksen, J., and Skovs-
gaard, T. (2004). Angiotensin-converting enzyme inhibitors for
cancer treatment? Acta Oncol. 43, 142–152.
Lorell, B.H. (1999). Role of angiotensin AT1, and AT2 receptors
in cardiac hypertrophy and disease. Am. J. Cardiol. 83,
48H–52H.
Marneros, A.G. and Olsen, B.R. (2001). The role of collagen-
derived proteolytic fragments in angiogenesis. Matrix Biol.
20, 337–345.
Mueller, S., Gothe, R., Siems, W.D., Vietinghoff, G., Paegelow,
I., and Reissmann, S. (2005). Potentiation of bradykinin
actions by analogues of the bradykinin potentiating nona-
peptide BPP9a. Peptides 26, 1235–1247.
Nagler, D.K., Storer, A.C., Portaro, F.C., Carmona, E., Juliano, L.,
and Menard, R. (1997). Major increase in endopeptidase
activity of human cathepsin B upon removal of occluding
loop contacts. Biochemistry 36, 12608–12615.
O’Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane,
W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., and Folkman, J.
(1997). Endostatin: an endogenous inhibitor of angiogenesis
and tumor growth. Cell 88, 277–285.
Parenti, A., Morbidelli, L., Ledda, F., Granger, H.J., and Ziche,
M. (2001). The bradykinin/B1 receptor promotes angiogene-
sis by up-regulation of endogenous FGF-2 in endothelium via
the nitric oxide synthase pathway. FASEB J. 15, 1487–1489.
Piot, J.M, Zhao, Q., Guillochon, D., Ricart, G., and Thomas, D.
(1992). Isolation and characterization of a bradykinin-poten-
tiating peptide from a bovine peptic hemoglobin hydrolysate.
FEBS Lett. 299, 75–79.
Pupilli, C., Lasagni, L., Romagnani, P., Bellini, F., Mannelli, M.,
Misciglia, N., Mavilia, C., Vellei U., Villari, D., and Serio, M.
(1999). Angiotensin II stimulates the synthesis and secretion
of vascular permeability factor/vascular endothelial growth
factor in human mesangial cells. J. Am. Soc. Nephrol. 10,
245–255.
Regoli, D. and Barabe, J. (1980). Pharmacology of bradykinin
and related kinins. Pharmacol. Rev. 32, 1–46.
Sasaki, T., Fukai, N., Mann, K., Göhring, W., Olsen, B.R., and
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